Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
Comparative Study between Posterior Approach with Mesopancreatectomy versus Standard Approach in Pancreatoduodenectomy: A Case Control Study
Background: Mesopancreas is the most common site for R1 resection and local recurrence. This study was designed to compare standard pancreatoduodenectomy (PD) versus posterior approach pancreatoduodenectomy PAPD in treating pancreatic head cancer.
Methods: All patients underwent PD for pancreatic head cancers from January 2006 to December 2015 were evaluated. Patients were divided into two groups. Group A patients underwent standard PD and group B underwent PAPD. The primary outcome was postoperative survival.
Results: The study included 210 patients in group A and 77 patients in group B. The mean blood loss was significantly lesser in PAPD group (P= 0.007). The number of patients with R1 resection was significantly higher after standard PD group (P=0.04). The median survival was 22 months in the standard groups and 23 months in PAPD (P= 0.001). 1-, 3- and 5-year actuarial survival were 41 %, 12%, and 0% in standard group and 51%, 21%, and 8% in PAPD.
Conclusion: PAPD allowed complete mesopancreatic excision and has the advantages of easier technique, less blood transfusion, increased R0 resection and better survival than standard PD.
Full Text Sources:
Abstract:
Views: 3088
Methods: All patients underwent PD for pancreatic head cancers from January 2006 to December 2015 were evaluated. Patients were divided into two groups. Group A patients underwent standard PD and group B underwent PAPD. The primary outcome was postoperative survival.
Results: The study included 210 patients in group A and 77 patients in group B. The mean blood loss was significantly lesser in PAPD group (P= 0.007). The number of patients with R1 resection was significantly higher after standard PD group (P=0.04). The median survival was 22 months in the standard groups and 23 months in PAPD (P= 0.001). 1-, 3- and 5-year actuarial survival were 41 %, 12%, and 0% in standard group and 51%, 21%, and 8% in PAPD.
Conclusion: PAPD allowed complete mesopancreatic excision and has the advantages of easier technique, less blood transfusion, increased R0 resection and better survival than standard PD.
Full Text Sources:
Abstract:
Views: 3088
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Dec 2025
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.